

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **VOLUNTARY ANNOUNCEMENT**

### **ASCLETIS' ASC36\_35FDC DEMONSTRATED POTENTIAL FOR ONCE-MONTHLY TO ONCE-QUARTERLY DOSING AND ROBUST WEIGHT-LOSS IN PRECLINICAL STUDIES PRESENTED AT EASD 2026**

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces the presentation of key preclinical data for its ASC36\_35FDC (ASC36\_35 co-formulation) at the 62<sup>nd</sup> European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28-October 2, 2026, in Milan, Italy (EASD 2026). ASC36\_35FDC is a once-monthly to once-quarterly fixed-dose combination injection of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist. The study was presented in a short oral discussion. The data demonstrated that ASC36\_35FDC exhibited a greater weight-loss trend than eloralintide/tirzepatide or MET-233i/tirzepatide co-formulations in a diet-induced obesity (DIO) rat model, as well as excellent formulation stability. Furthermore, once-weekly oral tablet formulation of ASC36\_35FDC has been developed by the Company.

#### **Key Highlights**

##### **Robust Weight-Loss: Demonstrating Potential Synergistic Effects in Preclinical Models**

In both DIO rat and non-human primate (NHP) models, ASC36\_35FDC showed greater additional reductions in body weight and food intake compared with ASC35 monotherapy, suggesting a potential synergistic effect of the combination.

In the DIO rat model, ASC36\_35FDC administered at 5 nmol/kg\_8 nmol/kg once every two days for a total of seven doses demonstrated substantial weight-loss. On Day 14, under the same dosing regimen, body weight decreased by 12.5% with the eloralintide/tirzepatide co-formulation, 16.8% with the MET-233i/tirzepatide co-formulation, and 24.8% with ASC36\_35FDC, a 98% and 47% greater relative reduction in body weight, respectively. Cumulative food intake was also substantially lower in the ASC36\_35FDC group compared to the two comparator groups.

## **Excellent Chemical and Physical Stability: No Evidence of Fibrotic Aggregation**

Long-term formulation stability is critical for peptide-based therapeutics. Under simulated storage conditions (200 rpm, 25°C, 168 hours), no fibril-induced aggregation was observed for ASC36\_35FDC across different concentrations, vehicles, or pH conditions. In contrast, cagrilintide exhibited substantial fibrotic aggregation under the same conditions. These findings demonstrate the excellent chemical and physical stability of ASC36\_35FDC and provide a strong foundation for further clinical development and potential large-scale manufacturing.

## **Pharmacokinetic Profile: Potential for Once-Monthly to Once-Quarterly Dosing**

In NHPs, the pharmacokinetic (PK) profile of ASC36\_35FDC was comparable to that observed following administration of ASC36 or ASC35 alone. The observed half-life of ASC36 and ASC35 demonstrated in ASC36\_35FDC were as long as 781 hours (approximately 33 days) and 721 hours (approximately 30 days), respectively, supporting once-monthly and the potential for once-quarterly subcutaneous administration in humans. This ultra-long-acting profile has the potential to improve treatment convenience and patient adherence, offering a more convenient therapeutic approach for chronic weight management.

## **Summary and Outlook**

ASC36\_35FDC is an internally developed combination therapy leveraging Ascletis' proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. By combining an amylin receptor agonist with a GLP-1R/GIPR dual agonist, ASC36\_35FDC is designed to leverage the complementary effects of these two therapeutic mechanisms. The preliminary preclinical data demonstrate promising activity across body-weight reduction, appetite suppression, formulation stability, and pharmacokinetic properties, supporting the potential of ASC36\_35FDC as a best-in-class therapeutic candidate.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC36\_35FDC successfully.

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hong Kong  
October 2, 2026

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*